January 20, 2021
AACC SmartBrief
Business Perspective
Thermo Fisher Scientific announced it will acquire Mesa Biotech for approximately $450 million in cash, with up to an additional $100 million in cash upon the completion of certain milestones.
Full Story: MassDevice (Boston) (1/19) 
LinkedIn Twitter Facebook Email
The Hanmi Covid-19 Quick Test, an antigen test that can detect COVID-19 infection within 30 minutes, will be released by Hanmi Pharmaceutical by February.
Full Story: Korea Biomedical Review (1/19) 
LinkedIn Twitter Facebook Email
Tech Briefs
Researchers from the Washington University School of Medicine in St. Louis have developed a blood test that can identify which patients with COVID-19 are at risk of severe disease or death and measures mitochondrial DNA present in the blood.
Full Story: Verdict Medical Devices (UK) (1/18) 
LinkedIn Twitter Facebook Email
Practice Briefs
The FDA has given emergency use authorization to Ortho Clinical Diagnostics for its VITROS SARS-CoV-2 Antigen Test, a high-volume COVID-19 antigen test, and to MatMaCorp for its Covid-19 2SF RNA test.
Full Story: Verdict Medical Devices (UK) (1/13) 
LinkedIn Twitter Facebook Email
The FDA has given emergency use authorization to PerkinElmer for its Nucleic Acid Detection Kit to test asymptomatic individuals.
Full Story: Medical Device & Diagnostic Industry online (1/14) 
LinkedIn Twitter Facebook Email
European regulators have given CE mark approval to Biomerica for its COVID-19 Antigen Rapid Test that can deliver results within 15 minutes.
Full Story: FDAnews (1/14) 
LinkedIn Twitter Facebook Email
Business/Corporate Briefs
A Series A financing round has raised $100 million for Delfi Diagnostics. The funds will be used to expand its team of machine learning experts and cancer researchers as well as to validate its next-generation blood-based cancer test.
Full Story: BioWorld (free content) (1/14) 
LinkedIn Twitter Facebook Email
The Biomedical Advanced Research and Development Authority has given DiaSorin Molecular additional funding to validate its Simplexa COVID-19 & Flu A/B Direct kit and its Simplexa COVID-19 Direct kit. The funds will also be used for studied needed to obtain 510(k) clearance from the FDA.
Full Story: Homeland Preparedness News (1/15) 
LinkedIn Twitter Facebook Email
Sharing AACC SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
Or copy and share your personalized link:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004